Andy Pollpeter joins HaydenCG as Director
Hayden Consulting Group is pleased to announce that Andy Pollpeter has joined the firm as Director. Welcome to HaydenCG, Andy. We’re thrilled to have you aboard!
October 7, 2021 - Boston, MA
Hayden Consulting Group, the BioPharma industry’s premier consultancy focused on strategy and analytics for Commercialization and Market Access, has welcomed Andy Pollpeter to the firm as Director.
Andy joins with a distinguished career and track record in the US and Europe spanning tenures with IQVIA, IMS Health/Amundsen Consulting, Milliman and Eli Lilly & Co. Andy’s experience includes all aspects of the commercialization experience from pipeline prioritization activities through to inline marketing, market access and loss of exclusivity strategies. Andy is also an expert at Real World Evidence (RWE) not just in analytics, but in terms of collecting, using, distributing, and advancing commercial performance by extracting maximum value from data assets.
In joining HaydenCG, Andy shares – “I love the consulting process and really working intimately with clients to move their business forward. The challenges facing the BioPharma industry are immense and intense, and that means having a great team that is 100% dedicated to solving complex problems. I have loved working with the leadership at Hayden previously in my career and can’t wait to immerse myself with the ‘best in breed’ team that I know Hayden has brought together.”
Andy recently returned from 3 years living in the UK, focused on supporting global pharma needs around Commercialization, RWE and Access, and has immersed himself back into the US BioPharma landscape (though he never really left). Andy joins the HaydenCG senior leadership team and anticipates adding to the rapid growth and expansion that HaydenCG has experienced.
About Hayden Consulting Group:
Hayden Consulting Group, founded in 2019, is the Life Science industry's premier Market Access and Commercialization strategic consultancy. Our singular focus is to deliver game-changing analytical and strategic guidance to radically transform the commercial trajectory of therapies, portfolios, and entire companies. We were founded to provide the BioPharma industry with needed expertise to solve the most pressing Access, Reimbursement, Policy, and Commercialization challenges in today's marketplace. Our services are designed to create competitive advantages, build strong analytical foundations, and turbo-charge growth plans. Nothing is cookie-cutter. The only common theme in what we do is 100% focus on our clients’ success. Follow us on LinkedIn